Review Article| Volume 20, ISSUE 9, P914-919, June 1935

Artificial pneumothorax in the treatment of lobar pneumonia

A review of forty pneumothorax-treated patients and one hundred patients treated by other methods
      This paper is only available as a PDF. To read, Please Download here.


      A series of 40 patients with lobar pneumonia treated by artificial pneumothorax is presented, with a mortality of 35 per cent. A control group of 100 patients with lobar pneumonia treated by other methods is also presented, with a mortality of 51 per cent. In addition to a decreased mortality, the chief benefits of artificial pneumothorax are relief of pain, dyspnea, cyanosis, and “toxicity.” It also shortens the febrile period sometimes by crisis, sometimes by lysis, and so lessens the number of hospital days per patient. Artificial pneumothorax is of little aid in the treatment of well-established pneumococcemias; it will not abort toxic psychoses, and it apparently has little influence on the prevention of the more severe complications of lobar pneumonia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Behrend A.
        • Cowper R.B.G.
        Artificial Pneumothorax in the Treatment of Lobar Pneumonia.
        J. A. M. A. 1934; 102: 1907
      1. Lilienthal, H.: Personal communication.